Drug Discovery and Development

The environment for drug discovery is becoming increasingly complex in terms of technologies related to new drug development due to changes including diversification in modalities and basic technologies and the spread of digital transformation (DX).

While these drug discovery technologies are becoming more sophisticated and achieving them becoming increasingly difficult, Kyorin aims to contribute to people’s health by pursuing new drug discovery strategies and drug discovery innovation for the continuous creation of high-value new products that meet medical needs.

One specific success was the out-licensing of our proprietary product KRP-M223 to Novartis in March 2025. We strongly hope that global development will move forward and that this product will help many patients around the world. Going forward, in addition to our core technologies in small molecule drug discovery, we will proactively use new external technologies to create new drugs that provide new value.

We will also actively work with external organizations with a focus on human resources development by raising researchers’ level of specialization and broadening their perspectives, with the aim of achieving the long-term vision “Vision 110.”